{
  "id": 13025051,
  "title": "Edwards Lifesciences CVP Daniel Lippis sells $53k in stock",
  "url": "https://urgent.news/2026/10/09/edwards-lifesciences-cvp-daniel-lippis-sells-53k-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-09T04:01:08.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/edwards-lifesciences-cvp-daniel-lippis-sells-53k-in-stock-93CH-4940146"
  },
  "original_language": "en",
  "account": "Edwards Lifesciences executive Daniel Lippis recently sold a portion of the company's stock, totaling $53,017. The transactions were conducted under a pre-approved trading plan on October 8, 2026. Lippis sold 619 shares at $85.65 per share, while simultaneously exercising 619 stock options, which were set to expire on May 6, 2027. Following the sale, Lippis still holds a total of 40,033.9103 shares of Edwards Lifesciences directly. The medical device company, valued at $48.6 billion, currently trades at $84.24, slightly below the insider's sale price. Analytical firm InvestingPro considers Edwards Lifesciences undervalued, citing its strong gross profit margin of 78% and 14.6% revenue growth over the last year.",
  "summary": null,
  "key_points": [
    "Edwards Lifesciences executive Daniel Lippis sold $53,017 worth of company stock.",
    "Lippis sold 619 shares at $85.65 per share and exercised 619 stock options.",
    "Lippis retains 40,033.9103 shares of Edwards Lifesciences after the sale."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}